(Total Views: 555)
Posted On: 05/24/2022 7:51:26 AM
Post# of 154759
Gestalt2,
Thank you for the clarification, this is not my recollection; however, my memory fails sometimes. I went back into the web and found that the deal was closed on or around August 2018:
https://www.biospectrumasia.com/news/83/11588...agene.html
At the time of the deal NP was in charge (president and CEO) and he had the ultimate responsibility of performing the required DD and closing the deal), also we was the one who presented the whole thing to us the shareholders.
Thank you for the clarification, this is not my recollection; however, my memory fails sometimes. I went back into the web and found that the deal was closed on or around August 2018:
https://www.biospectrumasia.com/news/83/11588...agene.html
Quote:
We are honored to soon have world-renowned cancer researcher Dr. Richard Pestell join CytoDyn as our Chief Medical Officer, with responsibility for leading all PRO 140 programs in non-HIV indications,” said Nader Pourhassan , Ph.D., President and CEO of CytoDyn. “We also have taken this important next step to acquire ProstaGene, which will allow Dr. Pestell to accelerate his CCR5 antagonist research related to cancer. As previously stated, our objective is to evaluate PRO 140 in expanded indications including certain cancers and immunological indications concurrent with advancing our promising HIV programs.
At the time of the deal NP was in charge (president and CEO) and he had the ultimate responsibility of performing the required DD and closing the deal), also we was the one who presented the whole thing to us the shareholders.
(8)
(0)
